MedTrace Logo

Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19

NCT04490486 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2022-05-12

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the safety of Umbilical Cord Tissue Derived Mesenchymal Stem Cells (UCMSCs) administered intravenously in patients with acute pulmonary inflammation due to COVID-19 with moderately severe symptoms

Conditions

  • COVID-19
  • Acute Respiratory Distress Syndrome
  • Corona Virus Infection

Interventions

BIOLOGICAL

UCMSCs

100 x 106 (100 million) UCMSCs delivered via peripheral intravenous infusion.

OTHER

Placebo

Placebo, a solution of 1% human serum albumin in Plasmalyte A, delivered via peripheral intravenous infusion

Sponsors & Collaborators

  • Joshua M Hare

    lead OTHER

Principal Investigators

  • Joshua M Hare, MD · ISCI/University of Miami Miller School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2024-06-01
Completion
2024-06-01
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04490486 on ClinicalTrials.gov